COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study to Compare the Efficacy of QAV680 Against Placebo in Treating Seasonal Allergic Rhinitis in an Environmental Exposure Chamber

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00784732
Recruitment Status : Completed
First Posted : November 4, 2008
Last Update Posted : November 18, 2016
Information provided by:

Brief Summary:
This study will compare the effectiveness of QAV680 against placebo in treating the symptoms of seasonal allergic rhinitis in an Environmental Exposure Chamber.

Condition or disease Intervention/treatment Phase
Seasonal Allergic Rhinitis Drug: QAV680 Drug: Mometasone Furoate Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 44 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Partially-blinded, Placebo-controlled, Two-way Crossover, Proof of Concept Study to Compare the Relative Efficacy of CRTh2 Receptor Antagonist, QAV680 Against Placebo in the Treatment of Allergic Rhinitis in an Environmental Exposure Chamber (EEC) Model
Study Start Date : September 2008
Actual Primary Completion Date : December 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hay Fever

Arm Intervention/treatment
Experimental: 1 Drug: QAV680
Experimental: 2 Drug: QAV680
Active Comparator: 3 Drug: Mometasone Furoate

Primary Outcome Measures :
  1. Total Nasal Symptom Score (TNSS) over the last 2 hours of exposure in the EEC Percentage nasal lavage eosinophil count post EEC [ Time Frame: TNSS: 6-8h during EEC exposure on Day 10 ]

Secondary Outcome Measures :
  1. Measure of nasal cytokines (ECP, IL-5, IL-13, PGD2, Eotaxin) [ Time Frame: After 8h exposure in EEC ]
  2. Absolute eosinophil count from nasal lavage collected [ Time Frame: During exposure in EEC ]
  3. Nasal airway patency assessed by acoustic rhinometry during exposure in the EEC [ Time Frame: During exposure in EEC ]
  4. Total Ocular Symptom Score measured during exposure in the EEC [ Time Frame: During exposure in EEC ]
  5. Assess pharmacokinetics of plasma QAV680 in patients with seasonal allergic rhinitis [ Time Frame: Through out study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Positive skin prick test to ragweed allergen
  • FEV1 must be ≥80% predicted value at screening and prior to entry into EEC on Day -2.
  • Patients must weigh at least 50 kg, and must have a body mass index (BMI) within the range of 18 to 35 kg/m2.
  • Non-smokers and ex-smokers (≤10 pack years and >6 months of smoking abstinence).
  • Understand and sign the written informed consent

Exclusion Criteria:

  • Patients requiring a change in the use of any prescription drugs within four (4) weeks prior to initial dosing.
  • Participation in any clinical investigation within four (4) weeks prior to initial dosing or longer if required by local regulations, and for any other limitation of participation based on local regulations.
  • Significant illness within two (2) weeks prior to initial dosing.
  • History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result.
  • A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.

Other protocol-defined inclusion/exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00784732

Layout table for location information
Novartis Investigator Site
Toronto, Canada
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Novartis Novartis Investigator Site
Layout table for additonal information
Responsible Party: External Affairs, Novartis Identifier: NCT00784732    
Other Study ID Numbers: CQAV680A2202
First Posted: November 4, 2008    Key Record Dates
Last Update Posted: November 18, 2016
Last Verified: November 2016
Keywords provided by Novartis:
Seasonal Allergic Rhinitis
Environmental Exposure Chamber
nasal lavage
Additional relevant MeSH terms:
Layout table for MeSH terms
Rhinitis, Allergic
Rhinitis, Allergic, Seasonal
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Mometasone Furoate
Anti-Inflammatory Agents
Dermatologic Agents
Anti-Allergic Agents